Zurich Cantonal Bank
RXRX icon

Zurich Cantonal Bank’s Recursion Pharmaceuticals RXRX Stock Holding History

Zurich Cantonal Bank’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-159,548
Closed -$653K – 3346
2025
Q4 		$653K Buy
+159,548
New +$790K ﹤0.01% 1612

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Zurich Cantonal Bank's RXRX Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Recursion Pharmaceuticals (RXRX) stake by 24% in Q2 2026, buying an estimated $173K and bringing the position to 266,883 shares worth $979K. The position accounts for ﹤0.01% of the portfolio, ranked #1567.

Zurich Cantonal Bank first reported a position in RXRX in Q3 2021 and has held it in 18 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Zurich Cantonal Bank held 266,883 shares of Recursion Pharmaceuticals worth $979K as of Q2 2026.
  • Zurich Cantonal Bank bought 52,032 Recursion Pharmaceuticals shares in Q2 2026, an estimated $173K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1567 holding.
  • Zurich Cantonal Bank first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.